VolitionRx Targets $5M Milestone with 97% Specificity Feline Cancer Test
VolitionRx has submitted a clinical manuscript for its Nu.Q® Vet Feline prototype assay, which detected 86% of feline lymphomas at 97% specificity. Publication is expected to unlock a $5 million milestone payment and pave the way for commercial launch to tap a market of over 73.8 million US cats.
1. Manuscript Submission and Assay Performance
VolitionRx submitted a peer-reviewed clinical manuscript demonstrating its Nu.Q® Vet Feline prototype assay detected 86% of intermediate-large cell lymphoma cases in cats with 97% specificity, representing what is expected to be the world’s first affordable blood-based liquid biopsy for feline cancer.
2. $5M Milestone Payment and Commercial Strategy
Publication of the study is projected to trigger a $5 million contractual milestone payment, following which VolitionRx plans to complete product development and distribute the test through reference laboratories and point-of-care platforms, leveraging its existing canine test infrastructure in over 20 countries.
3. Market Opportunity and TAM Expansion
With approximately 73.8 million pet cats in the U.S. and an estimated 1 in 5 lifetime cancer risk, including a senior segment of over 18 million cats aged 8+, VolitionRx anticipates the feline test could double its total addressable market in the $1.77 billion North American veterinary oncology sector.